Literature DB >> 9331072

PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

B K Rasheed1, T T Stenzel, R E McLendon, R Parsons, A H Friedman, H S Friedman, D D Bigner, S H Bigner.   

Abstract

The PTEN gene, located on 10q23, has recently been implicated as a candidate tumor suppressor gene in brain, breast and prostate tumors. In the present study, 123 brain tumors, including various grades and histological types of gliomas occurring in children and adults, were analyzed for PTEN mutations by SSCP assay and sequencing. Mutations in the PTEN gene were found in 13 of 42 adult glioblastomas and 3 of 13 adult anaplastic astrocytomas, whereas none of the 21 low-grade adult gliomas or the 22 childhood gliomas of all grades showed mutations. The single medulloblastoma with a mutation was a recurrent tumor that also possessed a p53 mutation. High-grade adult gliomas with PTEN mutations included cases that also contained gene amplification or p53 gene mutations, as well as cases that did not contain either of these abnormalities. There was no obvious relationship between presence of PTEN mutation and survival; however, there was a tendency for PTEN mutations to occur in older age group patients. This analysis suggest that PTEN gene mutations are restricted to high-grade adult gliomas and that this abnormality is independent of the presence or absence of gene amplification or p53 gene mutation in these tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331072

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  97 in total

Review 1.  Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis.

Authors:  M P Scheid; J R Woodgett
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

2.  Pten, a protean tumor suppressor.

Authors:  G L Mutter
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 3.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

4.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

5.  PTEN controls tumor-induced angiogenesis.

Authors:  S Wen; J Stolarov; M P Myers; J D Su; M H Wigler; N K Tonks; D L Durden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

6.  Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  S Ramaswamy; N Nakamura; F Vazquez; D B Batt; S Perera; T M Roberts; W R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.

Authors:  Bingbing Dai; Russell O Pieper; Dawei Li; Ping Wei; Mingguang Liu; Shiao Y Woo; Kenneth D Aldape; Raymond Sawaya; Keping Xie; Suyun Huang
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

Review 8.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

9.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

Authors:  K Podsypanina; L H Ellenson; A Nemes; J Gu; M Tamura; K M Yamada; C Cordon-Cardo; G Catoretti; P E Fisher; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

10.  Enhanced apoptosis in pilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumors.

Authors:  Akira Nakamizo; Takanori Inamura; Kiyonobu Ikezaki; Koji Yoshimoto; Satoshi Inoha; Masahiro Mizoguchi; Toshiyuki Amano; Masashi Fukui
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.